



A Pfizer Company

SAFETY DATA SHEET

Revision date: 12-Feb-2018

Version: 2.0

Page 1 of 12

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Ketorolac Tromethamine Injection, USP (Hospira Inc.)

Trade Name: Not established
Synonyms: Ketorolac trometamol
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as non-steroidal, anti-inflammatory drug (nsaid)

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 1A
Specific target organ systemic toxicity (repeated exposure): Category 2

Label Elements

Signal Word: Danger
Hazard Statements: H360D - May damage the unborn child
H373 - May cause damage to organs through prolonged or repeated exposure

Precautionary Statements: P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P260 - Do not breathe dust/fume/gas/mist/vapors/spray
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P314 - Get medical attention/advice if you feel unwell
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations

SAFETY DATA SHEET

Material Name: Ketorolac Tromethamine Injection, USP
(Hospira Inc.)
Revision date: 12-Feb-2018

Page 2 of 12

Version: 2.0



Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Ketorolac tromethamine	74103-07-4	Not Listed	Acute Tox.3 (H301) STOT RE 2 (H373) Repr.1A (H360D)	1.5-3.0
Ethanol	64-17-5	200-578-6	Flam. Liq. 2 (H225)	7 - 12
Sodium hydroxide	1310-73-2	215-185-5	Skin Corr.1A (H314)	**
Hydrochloric Acid	7647-01-0	231-595-7	Press. Gas Skin Corr.1A (H314) Acute Tox.3 (H331)	**

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Water for injection	7732-18-5	231-791-2	Not Listed	*
Sodium chloride	7647-14-5	231-598-3	Not Listed	*

Additional Information:

* Proprietary
** to adjust pH
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact:

Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact:

Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

SAFETY DATA SHEET

Material Name: Ketorolac Tromethamine Injection, USP
(Hospira Inc.)
Revision date: 12-Feb-2018

Page 3 of 12

Version: 2.0

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical product used as non-steroidal, anti-inflammatory drug (nsaid)

SAFETY DATA SHEET

Material Name: Ketorolac Tromethamine Injection, USP
(Hospira Inc.)
Revision date: 12-Feb-2018

Page 4 of 12

Version: 2.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Ketorolac tromethamine

Pfizer OEL TWA-8 Hr: 30 µg/m³

Ethanol

ACGIH Threshold Limit Value (STEL)	1000 ppm
Australia TWA	1000 ppm
	1880 mg/m ³
Austria OEL - MAKs	1000 ppm
	1900 mg/m ³
Belgium OEL - TWA	1000 ppm
	1907 mg/m ³
Bulgaria OEL - TWA	1000 mg/m ³
Czech Republic OEL - TWA	1000 mg/m ³
Denmark OEL - TWA	1000 ppm
	1900 mg/m ³
Estonia OEL - TWA	500 ppm
	1000 mg/m ³
Finland OEL - TWA	1000 ppm
	1900 mg/m ³
France OEL - TWA	1000 ppm
	1900 mg/m ³
Germany - TRGS 900 - TWAs	500 ppm
	960 mg/m ³
Germany (DFG) - MAK	500 ppm
	960 mg/m ³
Greece OEL - TWA	1000 ppm
	1900 mg/m ³
Hungary OEL - TWA	1900 mg/m ³
Latvia OEL - TWA	1000 mg/m ³
Lithuania OEL - TWA	500 ppm
	1000 mg/m ³
Netherlands OEL - TWA	260 mg/m ³
OSHA - Final PELs - TWAs:	1000 ppm
	1900 mg/m ³
Poland OEL - TWA	1900 mg/m ³
Portugal OEL - TWA	1000 ppm
Romania OEL - TWA	1000 ppm
	1900 mg/m ³
Russia OEL - TWA	1000 mg/m ³
Slovakia OEL - TWA	500 ppm
	960 mg/m ³
Slovenia OEL - TWA	1000 ppm
	1900 mg/m ³
Sweden OEL - TWAs	500 ppm
	1000 mg/m ³
Switzerland OEL - TWAs	500 ppm
	960 mg/m ³
Vietnam OEL - TWAs	1000 mg/m ³

SAFETY DATA SHEET

Material Name: Ketorolac Tromethamine Injection, USP
(Hospira Inc.)
Revision date: 12-Feb-2018

Page 5 of 12

Version: 2.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Sodium hydroxide

ACGIH Ceiling Threshold Limit:	2 mg/m ³
Australia PEAK	2 mg/m ³
Austria OEL - MAKs	2 mg/m ³
Bulgaria OEL - TWA	2.0 mg/m ³
Czech Republic OEL - TWA	1 mg/m ³
Estonia OEL - TWA	1 mg/m ³
France OEL - TWA	2 mg/m ³
Greece OEL - TWA	2 mg/m ³
Hungary OEL - TWA	2 mg/m ³
Japan - OELs - Ceilings	2 mg/m ³
Latvia OEL - TWA	0.5 mg/m ³
OSHA - Final PELs - TWAs:	2 mg/m ³
Poland OEL - TWA	0.5 mg/m ³
Slovakia OEL - TWA	2 mg/m ³
Slovenia OEL - TWA	2 mg/m ³
Sweden OEL - TWAs	1 mg/m ³
Switzerland OEL - TWAs	2 mg/m ³

Sodium chloride

Latvia OEL - TWA	5 mg/m ³
Lithuania OEL - TWA	5 mg/m ³

Hydrochloric Acid

ACGIH Ceiling Threshold Limit:	2 ppm
Australia PEAK	5 ppm
	7.5 mg/m ³
Austria OEL - MAKs	5 ppm
	8 mg/m ³
Belgium OEL - TWA	5 ppm
	8 mg/m ³
Bulgaria OEL - TWA	5 ppm
	8.0 mg/m ³
Cyprus OEL - TWA	5 ppm
	8 mg/m ³
Czech Republic OEL - TWA	8 mg/m ³
Estonia OEL - TWA	5 ppm
	8 mg/m ³
Germany - TRGS 900 - TWAs	2 ppm
	3 mg/m ³
Germany (DFG) - MAK	2 ppm
	3.0 mg/m ³
Greece OEL - TWA	5 ppm
	7 mg/m ³
Hungary OEL - TWA	8 mg/m ³
Ireland OEL - TWAs	5 ppm
	8 mg/m ³
Italy OEL - TWA	5 ppm
	8 mg/m ³
Japan - OELs - Ceilings	2 ppm
	3.0 mg/m ³

SAFETY DATA SHEET

Material Name: Ketorolac Tromethamine Injection, USP
(Hospira Inc.)
Revision date: 12-Feb-2018

Page 6 of 12

Version: 2.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Latvia OEL - TWA	5 ppm 8 mg/m ³
Lithuania OEL - TWA	5 ppm 8 mg/m ³
Luxembourg OEL - TWA	5 ppm 8 mg/m ³
Malta OEL - TWA	5 ppm 8 mg/m ³
Netherlands OEL - TWA	8 mg/m ³
Poland OEL - TWA	5 mg/m ³
Portugal OEL - TWA	5 ppm 8 mg/m ³
Romania OEL - TWA	5 ppm 8 mg/m ³
Slovakia OEL - TWA	5 ppm 8.0 mg/m ³
Slovenia OEL - TWA	5 ppm 8 mg/m ³
Spain OEL - TWA	5 ppm 7.6 mg/m ³
Switzerland OEL -TWAs	2 ppm 3.0 mg/m ³
Vietnam OEL - TWAs	5 mg/m ³

Sodium chloride

Pfizer Occupational Exposure Band (OEB): OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³)

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands:

Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes:

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin:

Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection:

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.)

SAFETY DATA SHEET

Material Name: Ketorolac Tromethamine Injection, USP
(Hospira Inc.)
Revision date: 12-Feb-2018

Page 7 of 12

Version: 2.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Solution	Color:	Clear to light yellow
Odor:	Alcohol Slight	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility:	No data available
Water Solubility:	No data available
Solubility:	Soluble: Water
pH:	6.9-7.9
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)	

Sodium chloride
No data available

Ketorolac tromethamine
No data available

Ethanol
No data available

Water for injection
No data available

Hydrochloric Acid
No data available

Sodium hydroxide
No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s):	No data available
Vapor Pressure (kPa):	No data available
Vapor Density (g/ml):	No data available
Relative Density:	No data available
Specific Gravity:	0.991
Viscosity:	No data available

Flammability:

Autoignition Temperature (Solid) (°C):	No data available
Flammability (Solids):	No data available
Flash Point (Liquid) (°C):	55 (ethanol)
Upper Explosive Limits (Liquid) (% by Vol.):	No data available
Lower Explosive Limits (Liquid) (% by Vol.):	No data available

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Reactivity:	No data available
Chemical Stability:	Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties:	No data available
Conditions to Avoid:	Fine particles (such as mists) may fuel fires/explosions. As a precautionary measure, keep away from heat sources and electrostatic discharge.

Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products:	No data available

SAFETY DATA SHEET

Material Name: Ketorolac Tromethamine Injection, USP
(Hospira Inc.)
Revision date: 12-Feb-2018

Page 8 of 12

Version: 2.0

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information:

The information included in this section describes the potential hazards of the individual ingredients.

Short Term:

Accidental ingestion may cause effects similar to those seen in clinical use. Individuals sensitive to this chemical or other materials in its chemical class may develop allergic reactions.

Known Clinical Effects:

Other nonsteroidal anti-inflammatory drugs (NSAIDs) are known to impact delivery, late fetal development, and lactation. Ingestion of this material may cause effects similar to those seen in clinical use including serious gastrointestinal toxicity such as bleeding, ulceration, and perforation and kidney toxicity. Clinical use of this drug has caused headache, dizziness, blurred vision, ringing of the ears, skin rash, itching, swelling, and liver effects.

Acute Toxicity: (Species, Route, End Point, Dose)

Sodium chloride

Rat Oral LD50 3000 mg/kg
Mouse Oral LD50 4000 mg/kg

Ketorolac tromethamine

Rat Oral LD50 189 mg/kg
Mouse Oral LD50 293mg/kg

Ethanol

Mouse Oral LD50 3,450 g/m³
Rat Oral LD50 7,060mg/kg
Mouse Inhalation LC50 4h 39g/m³
Rat Inhalation LC50 10h 20,000ppm

Sodium hydroxide

Mouse IP LD50 40 mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium chloride

Eye Irritation Rabbit Moderate
Skin Irritation Rabbit Mild

Ethanol

Eye Irritation Rabbit Severe

Hydrochloric Acid

Skin Irritation Severe
Eye Irritation Severe

Sodium hydroxide

Eye Irritation Rabbit Severe
Skin Irritation Rabbit Severe

SAFETY DATA SHEET

Material Name: Ketorolac Tromethamine Injection, USP
(Hospira Inc.)
Revision date: 12-Feb-2018

Page 9 of 12

Version: 2.0

11. TOXICOLOGICAL INFORMATION

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Ketorolac tromethamine

Reproductive & Fertility-Females	Rat	Oral	16 mg/kg/day	NOAEL	Negative
Reproductive & Fertility-Males	Rat	Oral	9 mg/kg/day	NOAEL	Negative
Prenatal & Postnatal Development	Rabbit	Oral	3.6 mg/kg/day	NOAEL	Negative
Prenatal & Postnatal Development	Rat	Oral	10 mg/kg/day	NOAEL	Negative

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Ketorolac tromethamine

Bacterial Mutagenicity (Ames)	<i>Salmonella</i> , <i>E. coli</i>	Negative
Unscheduled DNA Synthesis	Not specified	Negative
<i>In Vivo</i> Micronucleus	Mouse	Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Ketorolac tromethamine

24 Month(s)	Rat	Oral	5 mg/kg/day	NOAEL	Not carcinogenic
18 Month(s)	Mouse	Oral	2 mg/kg/day	NOAEL	Not carcinogenic

Carcinogen Status:

Carcinogenicity of the mixture has not been determined. Alcohol is listed as a carcinogen by IARC. The IARC monograph examining the carcinogenic potential of ethanol examined only alcoholic beverages. See below

Ethanol

IARC: Group 1 (Carcinogenic to Humans)

Hydrochloric Acid

IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview:

The environmental characteristics of this mixture have not been fully evaluated. Releases to the environment should be avoided.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Ethanol

Fingerling Trout	NPDES	LC50	24 Hours	11,200 mg/L
<i>Oncorhynchus mykiss</i> (Rainbow Trout)	NPDES	LC50	96 Hours	12,900 mg/L
<i>Pimephales promelas</i> (Fathead Minnow)	NPDES	LC50	96 Hours	14,200 mg/L

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

SAFETY DATA SHEET

Material Name: Ketorolac Tromethamine Injection, USP
(Hospira Inc.)
Revision date: 12-Feb-2018

Page 10 of 12

Version: 2.0

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Ketorolac tromethamine

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	Not Listed

Ethanol

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen 4/29/2011 in alcoholic beverages developmental toxicity 10/1/1987 in alcoholic beverages
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-578-6

Sodium hydroxide

CERCLA/SARA 313 Emission reporting	Not Listed
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	1000 lb 454 kg
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present

SAFETY DATA SHEET

Material Name: Ketorolac Tromethamine Injection, USP
(Hospira Inc.)
Revision date: 12-Feb-2018

Page 11 of 12

Version: 2.0

15. REGULATORY INFORMATION

Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 5
EU EINECS/ELINCS List	Schedule 6
	215-185-5

Water for injection

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

Sodium chloride

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-598-3

Hydrochloric Acid

CERCLA/SARA 313 Emission reporting	1.0 %
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	5000 lb
CERCLA/SARA - Section 302 Extremely Hazardous TPQs	2270 kg
CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs	500 lb
California Proposition 65	5000 lb
Inventory - United States TSCA - Sect. 8(b)	Not Listed
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Present
EU EINECS/ELINCS List	Schedule 5
	Schedule 6
	231-595-7

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.3; H301 - Toxic if swallowed
 Acute toxicity, inhalation-Cat.3; H331 - Toxic if inhaled
 Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage
 Reproductive toxicity-Cat.1A; H360D - May damage the unborn child
 Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure
 Flammable liquids-Cat.2; H225 - Highly flammable liquid and vapor

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 8 - Exposure Controls / Personal Protection.

SAFETY DATA SHEET

Material Name: Ketorolac Tromethamine Injection, USP
(Hospira Inc.)

Page 12 of 12

Revision date: 12-Feb-2018

Version: 2.0

Revision date: 12-Feb-2018

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet